Compare Abbott Laboratories (ABT) vs Blackstone Inc (BX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs Blackstone Inc — how do they compare? Abbott Laboratories trades at $109.48 (market cap $187.95B), while Blackstone Inc trades at $148 (market cap $117.44B). The key difference: Abbott Laboratories is the larger of the two by market cap, and Blackstone Inc pays the higher dividend (3.55%). Which is the better fit depends on your goals.
| ABT | BX | |
|---|---|---|
Market Cap | $187.95B | $117.44B |
Sector | Health | Financials |
52-Week High | $136.62 | $188.68 |
52-Week Low | $82.57 | $102.12 |
Enterprise Value | $214.96B | — |
Dividend Yield | 2.32% | 3.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
Blackstone (BX) trades at $141.67, up 3.31% today, near its consensus price target of $144.00. The stock shows strong bullish technical signals and has consistently beaten earnings estimates in recent quarters. Recent news highlights strategic acquisitions, including a stake in Air Canada's Aeroplan program and a $25.3 billion Australian home loan portfolio purchase from HSBC, signaling aggressive growth and diversification.
Outlook remains positive with robust revenue growth and high profitability, though elevated valuation ratios and overbought RSI levels suggest near-term caution. Key risks include market volatility and integration challenges from recent deals. Analyst consensus is strongly bullish, supporting a favorable long-term view.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Blackstone Inc
Blackstone is one of the world's largest alternative asset managers with $940.8 billion in total asset under management, including $683.8 billion in fee-earning asset under management, at the end of June 2022.
Read more on BX →
